Wensing AMJ - Search Results

1

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.

Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing AMJ, Lee H, Grant P, Nastouli E, Lambert J, Pace M, Salasc F, Monit C, Innes AJ, Muir L, Waters L, Frater J, Lever AML, Edwards SG, Gabriel IH, Olavarria E. Gupta RK, et al. Among authors: wensing amj. Nature. 2019 Apr;568(7751):244-248. doi: 10.1038/s41586-019-1027-4. Epub 2019 Mar 5. Nature. 2019. PMID: 30836379 Free PMC article.

2

Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.

van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M. van Maarseveen NM, et al. J Infect Dis. 2007 Feb 1;195(3):399-409. doi: 10.1086/510533. Epub 2006 Dec 29. J Infect Dis. 2007. PMID: 17205479

3

Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

Nijhuis M, Wensing AM, Bierman WF, de Jong D, Kagan R, Fun A, Jaspers CA, Schurink KA, van Agtmael MA, Boucher CA. Nijhuis M, et al. J Infect Dis. 2009 Sep 1;200(5):698-709. doi: 10.1086/605329. J Infect Dis. 2009. PMID: 19627247

4

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

Wensing AM, van Maarseveen NM, Nijhuis M. Wensing AM, et al. Antiviral Res. 2010 Jan;85(1):59-74. doi: 10.1016/j.antiviral.2009.10.003. Epub 2009 Oct 22. Antiviral Res. 2010. PMID: 19853627 Review.

5

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.

Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M. Verheyen J, et al. AIDS. 2010 Mar 13;24(5):669-73. doi: 10.1097/QAD.0b013e32833160fa. AIDS. 2010. PMID: 19926962

6

Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.

Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM, Nijhuis M. Fun A, et al. J Antimicrob Chemother. 2010 Nov;65(11):2300-4. doi: 10.1093/jac/dkq319. Epub 2010 Aug 24. J Antimicrob Chemother. 2010. PMID: 20736234

7

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.

Symons J, van Lelyveld SF, Hoepelman AI, van Ham PM, de Jong D, Wensing AM, Nijhuis M. Symons J, et al. J Antimicrob Chemother. 2011 Apr;66(4):890-5. doi: 10.1093/jac/dkq535. Epub 2011 Jan 28. J Antimicrob Chemother. 2011. PMID: 21393136

8

Evolutionary pathways of transmitted drug-resistant HIV-1.

Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM. Pingen M, et al. J Antimicrob Chemother. 2011 Jul;66(7):1467-80. doi: 10.1093/jac/dkr157. Epub 2011 Apr 18. J Antimicrob Chemother. 2011. PMID: 21502281 Review.

9

Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.

van Maarseveen NM, Wensing AM, de Jong D, Beilhartz GL, Obikhod A, Tao S, Pingen M, Arends JE, Hoepelman AI, Schinazi RF, Götte M, Nijhuis M. van Maarseveen NM, et al. Antivir Ther. 2011;16(7):1123-30. doi: 10.3851/IMP1912. Antivir Ther. 2011. PMID: 22024528 Free PMC article.

10

Human Immunodeficiency Virus Gag and protease: partners in resistance.

Fun A, Wensing AM, Verheyen J, Nijhuis M. Fun A, et al. Retrovirology. 2012 Aug 6;9:63. doi: 10.1186/1742-4690-9-63. Retrovirology. 2012. PMID: 22867298 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

173 results

Search Page